S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Laser breakthrough could send stock soaring 2,467% (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Laser breakthrough could send stock soaring 2,467% (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Laser breakthrough could send stock soaring 2,467% (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Laser breakthrough could send stock soaring 2,467% (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Forecast, Price & News

$2.22
-0.01 (-0.45%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.17
$2.30
50-Day Range
$1.80
$2.81
52-Week Range
$1.74
$6.24
Volume
27,008 shs
Average Volume
67,644 shs
Market Capitalization
$22.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Cocrystal Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
440.5% Upside
$12.00 Price Target
Short Interest
Healthy
0.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.20mentions of Cocrystal Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$2 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.13) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

198th out of 983 stocks

Pharmaceutical Preparations Industry

85th out of 486 stocks


COCP stock logo

About Cocrystal Pharma (NASDAQ:COCP) Stock

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

COCP Stock News Headlines

"How war impacts the stock market"
Russia's invasion of Ukraine has already sent the stock market down 10%. But that's just the opening act for the new Russia-China Alliance. There's a major event involving China that's heating up... and it could boil over as soon as April 16th, 2023. Click Here to Learn How to Protect Your Retirement
H.C. Wainwright Keeps Their Buy Rating on Cocrystal Pharma (COCP)
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
COCP Cocrystal Pharma, Inc.
See More Headlines

COCP Price History

COCP Company Calendar

Last Earnings
3/29/2023
Today
6/03/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
13
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+440.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.01 million
Cash Flow
$0.17 per share
Book Value
$3.41 per share

Miscellaneous

Free Float
9,614,000
Market Cap
$22.58 million
Optionable
Not Optionable
Beta
1.20

Key Executives

  • Sam Lee
    President & Co-Chief Executive Officer
  • James Joseph Martin
    Co-Chief Executive Officer, CFO & Secretary
  • Luz Pascual
    Vice President-Clinical Development













COCP Stock - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" COCP shares.
View COCP analyst ratings
or view top-rated stocks.

What is Cocrystal Pharma's stock price forecast for 2023?

1 equities research analysts have issued 1-year price objectives for Cocrystal Pharma's stock. Their COCP share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 440.5% from the stock's current price.
View analysts price targets for COCP
or view top-rated stocks among Wall Street analysts.

How have COCP shares performed in 2023?

Cocrystal Pharma's stock was trading at $1.95 at the beginning of the year. Since then, COCP shares have increased by 13.8% and is now trading at $2.22.
View the best growth stocks for 2023 here
.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 34,100 shares, a decrease of 13.7% from the April 30th total of 39,500 shares. Based on an average trading volume of 70,200 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.5% of the company's shares are sold short.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our COCP earnings forecast
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Wednesday, March, 29th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.17.

When did Cocrystal Pharma's stock split?

Cocrystal Pharma shares reverse split on the morning of Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

What is Cocrystal Pharma's stock symbol?

Cocrystal Pharma trades on the NASDAQ under the ticker symbol "COCP."

Who are Cocrystal Pharma's major shareholders?

Cocrystal Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.18%), Sabby Management LLC (0.65%) and Susquehanna International Group LLP (0.20%). Insiders that own company stock include Phillip Md Et Al Frost, Raymond F Schinazi and Richard C Pfenniger, Jr.
View institutional ownership trends
.

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cocrystal Pharma's stock price today?

One share of COCP stock can currently be purchased for approximately $2.22.

How much money does Cocrystal Pharma make?

Cocrystal Pharma (NASDAQ:COCP) has a market capitalization of $22.58 million and generates $2.01 million in revenue each year. The company earns $-38,840,000.00 in net income (profit) each year or ($4.8912) on an earnings per share basis.

How can I contact Cocrystal Pharma?

Cocrystal Pharma's mailing address is 19805 N. CREEK PARKWAY, BOTHELL WA, 98011. The official website for the company is www.cocrystalpharma.com. The company can be reached via phone at (305) 425-1780 or via email at cocp@jtcir.com.

This page (NASDAQ:COCP) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -